ClinicalTrials.gg
RecruitingNCT05712577MARFANPSYUpdated Nov 10, 2026

Psychological Support in Adult Patients With Marfan Syndrome

An observational study in Rare Diseases, Marfan Syndrome and Psychology, Social, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by IRCCS Policlinico S. Donato · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.
Updated Nov 10, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
125
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to identify key factors leading to psychotherapy or psychological support in adult subjects with Marfan syndrome (MSF). the main questions it aims to answer are:

  • Understand and define which internal variables of the individual drive this request for psychological support;
  • To learn about verify the impact that the clinical manifestations of MSF have on psychosocial aspects, self-esteem, subjective perception of the disease and coping mechanisms.
Read the detailed description

Patients following psychological interview during follow-up visits will be enrolled in the study.

The following self-report questionnaires will be used in understanding the impact the syndrome has on mental health and quality of life:

  • Rosenberg Self- Esteem: 10 item Likert scale for assessing self-esteem;
  • SF 36: 36 item scale assessing eight domains: physical functioning physical role limitations; bodily pain; general health perceptions; energy/vitality; social functioning; emotional role limitations and mental health;
  • Cope NVI: to test measures coping behaviors as potential responses to stressors like social support, avoidance strategies, positive attitude, problem orientation and transcendent orientation;
  • OQ45.2: measure of general psychological distress.
02

Conditions studied

  • Rare Diseases
  • Marfan Syndrome
  • Psychology, Social

Keywords

  • Marfan syndrome
  • Psychological support
  • Self-report
03

In context

Rare Diseases

592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.

This study's planned enrollment of 125 is close to the median of 133 across 208 observational studies indexed under Rare Diseases.

Browse Rare Diseases studies →

Lead sponsor

IRCCS Policlinico S. Donato is the lead sponsor of 105 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with MFS who have requested psychological support/psychotherapy and patients who have never requested psychological support/psychotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects affected by Marfan syndrome;
  • Subjects currently in follow-up at Cardiovascular Genetic Centre, IRCCS Policlinico San Donato;
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Subjects with cognitive deficits
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
125 participants (estimated)
Patient registry
No

Groups and cohorts

  • MFS_PT+

    MFS patients who followed psychological support/psychotherapy

    Other: Questionnaire

  • MFS_PT-

    MFS patients who never followed psychological support/psychotherapy

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    Rosenberg Self- Esteem scale

  • OtherQuestionnaire

    Short Form 36 scale

  • OtherQuestionnaire

    Coping orientation to the problems experienced - New Version in Italian

  • OtherQuestionnaire

    Outcome Questionnaire - version 42.5

06

What researchers measure

Primary outcomes

  1. Questionnaire performance

    Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables. Questionnaire scoring: \- COPE NVI: scoring between 60 and 240; higher score means better outcome

    Time frame: 8 Months

  2. Questionnaire performance

    Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables. Questionnaire scoring: \- Short Form-36: scoring between 0 and 100; higher score means better outcome

    Time frame: 8 Months

  3. Questionnaire performance

    Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables. Questionnaire scoring: \- Rosenberg Self- Esteem scale: scoring between 0 and 30; higher score means better outcome

    Time frame: 8 Months

  4. Questionnaire performance

    Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables. Questionnaire scoring: \- Outcome questionnaire 42.5: socring between 0 and 180; clinical cut-off value is 64, higher score means worse outcome

    Time frame: 8 Months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2023 (actual). Primary completion is estimated for Feb 2027, 49 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2024 → Feb 2027 and completion Oct 2024 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Feb 3, 2023
StartActual
Jan 9, 2023
Primary completionEst.
Feb 9, 2027was Oct 2024
CompletionEst.
Oct 9, 2027was Oct 2024
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • IRCCS Policlinico San Donato · San Donato Milanese, Italy
Show 1 removed
  • IRCCS Policlinico San Donato · San Donato Milanese, Italy
Nov 10, 2026
Primary completion
Oct 9, 2024→Feb 9, 2027
Nov 10, 2026
Study completion
Oct 9, 2024→Oct 9, 2027
Nov 10, 2026
Primary outcomes
4 description edited
What changed in the outcomes
  • DescriptionQuestionnaire performance: how it is measured was reworded
  • DescriptionQuestionnaire performance#2: how it is measured was reworded
  • DescriptionQuestionnaire performance#3: how it is measured was reworded
  • DescriptionQuestionnaire performance#4: how it is measured was reworded
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    1 site added, 1 site removed
    Show site
    • IRCCS Policlinico San Donato · San Donato Milanese, Italy
    Show 1 removed
    • IRCCS Policlinico San Donato · San Donato Milanese, Italy
    Primary completion Oct 9, 2024→Feb 9, 2027
    Study completion Oct 9, 2024→Oct 9, 2027
    Primary outcomes 4 description edited
    What changed in the outcomes
    • DescriptionQuestionnaire performance: how it is measured was reworded
    • DescriptionQuestionnaire performance#2: how it is measured was reworded
    • DescriptionQuestionnaire performance#3: how it is measured was reworded
    • DescriptionQuestionnaire performance#4: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05712577
Responsible party
Alessandro Pini (Principal Investigator, IRCCS Policlinico S. Donato) — Principal investigator
First posted
Feb 3, 2023
Start date
Jan 9, 2023
Primary completion
Feb 9, 2027 (estimated)
Completion
Oct 9, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Alessandro Pini, MD
Contact
alessandro.pini@grupposandonato.it
+390252774705
Alessandro Pini, MD
principal investigator · Cardiovascular-Gentic Centre, IRCCS Policlinico San Donato

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion